Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections | Zendy

Matthew Sims | Zendy; Valeri Mariyanovski | Zendy; Patrick McLeroth | Zendy; Wayne Akers | Zendy; YuChieh Lee | Zendy; Michelle Brown | Zendy; Jiejun Du | Zendy; Alison Pedley | Zendy; Nicholas A. Kartsonis | Zendy; Amanda Paschke | Zendy

Open Access

Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections

Author(s) -

Matthew Sims,

Valeri Mariyanovski,

Patrick McLeroth,

Wayne Akers,

YuChieh Lee,

Michelle Brown,

Jiejun Du,

Alison Pedley,

Nicholas A. Kartsonis,

Amanda Paschke

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx139

Subject(s) - imipenem/cilastatin , cilastatin , imipenem , medicine , tolerability , adverse effect , antibacterial agent , gastroenterology , pharmacology , antibiotics , microbiology and biotechnology , antibiotic resistance , biology

The β-lactamase inhibitor relebactam can restore imipenem activity against imipenem non-susceptible pathogens.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research